Cargando…

Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years

OBJECTIVE: To evaluate changes in baseline patient characteristics and entry criteria of randomised, controlled studies of tumour necrosis factor alpha (TNFα) inhibitors in rheumatoid arthritis (RA) patients. METHODS: A systematic literature review was performed using predefined inclusion criteria t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rahman, Mahboob U, Buchanan, Jacqui, Doyle, Mittie K, Hsia, Elizabeth C, Gathany, Timothy, Parasuraman, Shreekant, Aletaha, Daniel, Matteson, Eric L, Conaghan, Philip G, Keystone, Edward, van der Heijde, Désireé, Smolen, Josef S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Group 2011
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3147244/ https://www.ncbi.nlm.nih.gov/pubmed/21708910 http://dx.doi.org/10.1136/ard.2010.146043

Ejemplares similares

Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
por: Smolen, Josef S, et al.
Publicado: (2014)

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
por: Smolen, Josef S, et al.
Publicado: (2012)

Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2011)

Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study
por: Smolen, Josef S, et al.
Publicado: (2015)

Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial
por: Conaghan, Philip G, et al.
Publicado: (2011)

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search
por: Schoels, Monika, et al.
Publicado: (2010)

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction
por: Smolen, Josef S, et al.
Publicado: (2011)

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate
por: Smolen, Josef S, et al.
Publicado: (2013)

Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation
por: Kirkham, Bruce W, et al.
Publicado: (2014)

Developments in the clinical understanding of rheumatoid arthritis
por: Smolen, Josef S, et al.
Publicado: (2009)

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
por: Keystone, Edward, et al.
Publicado: (2014)

Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study
por: Visvanathan, Sudha, et al.
Publicado: (2010)

Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials
por: Aletaha, Daniel, et al.
Publicado: (2015)

Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
por: Keystone, E C, et al.
Publicado: (2008)

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs
por: Radner, Helga, et al.
Publicado: (2014)

Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire
por: Haraoui, Boulos, et al.
Publicado: (2011)

Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data
por: Dougados, M, et al.
Publicado: (2008)

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
por: Keystone, Edward C, et al.
Publicado: (2017)

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement
por: Schoels, Monika M, et al.
Publicado: (2013)

Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients
por: Radner, Helga, et al.
Publicado: (2015)

Rheumatoid interstitial lung disease in Canterbury New Zealand: prevalence, risk factors and long-term outcomes—protocol for a population-based retrospective study
por: Farquhar, Hamish, et al.
Publicado: (2022)

Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis
por: Landewé, Robert, et al.
Publicado: (2015)

Value of self-performed joint counts in rheumatoid arthritis patients near remission
por: Radner, Helga, et al.
Publicado: (2012)

The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound
por: Dougados, Maxime, et al.
Publicado: (2013)

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Kay, Jonathan, et al.
Publicado: (2015)

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
por: Emery, P, et al.
Publicado: (2008)

Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques
por: Conaghan, Philip G, et al.
Publicado: (2016)

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
por: Wells, G, et al.
Publicado: (2008)

Treating rheumatoid arthritis to target: recommendations of an international task force
por: Smolen, Josef S, et al.
Publicado: (2010)

The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
por: Smolen, Josef S, et al.
Publicado: (2008)

Evolution of cost structures in rheumatoid arthritis over the past decade
por: Huscher, Dörte, et al.
Publicado: (2015)

Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns
por: Platzer, Alexander, et al.
Publicado: (2019)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
por: Schiff, Michael, et al.
Publicado: (2014)

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
por: Ritchlin, Christopher, et al.
Publicado: (2014)

Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature
por: Visser, K, et al.
Publicado: (2008)

Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study
por: Song, Yeo-Jin, et al.
Publicado: (2022)

Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
por: Takeuchi, Tsutomu, et al.
Publicado: (2016)

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
por: Salliot, C, et al.
Publicado: (2008)

Remission by composite scores in rheumatoid arthritis: are ankles and feet important?
por: Kapral, Theresa, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_2idr5mmgamnmjs45ku2b01e6bq